详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 预警期刊

作者：

机构： [1]North Sichuan Medical College, Institute of Basic Medicine and Forensic Medicine, Sichuan, China. [2]Sichuan Key Laboratory of Medical Imaging and school of Medicine Imaging, North Sichuan Medical College, Sichuan, China. [3]Department of Academician (expert) Workstation, Biological Targeting Laboratory of Breast Cancer, Breast and Thyroid Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan, China. [4]Wuxi School of Medicine, Jiangnan University, Jiangsu, China.

出处：

DOI：

ISSN：

关键词： breast cancer PTK2 prognosis immune infiltrates biomarker

摘要：

PTK2 is highly expressed in many cancers and is involved in cell growth, survival, migration, and invasion. However, the prognostic value of PTK2 and its potential function remain unclear in breast cancer. Therefore, we performed a comprehensive analysis of multiple public databases to explore the roles of PTK2. By integrating multiple datasets, we found that PTK2 mRNA expression in breast cancer tissue was higher than that in normal breast tissue or adjacent tissue. High PTK2 expression was associated with lymph node metastasis stage, tumor stage, breast cancer type, age, TP53 mutation, and gender and significantly predicted a poor survival outcome in breast cancer patients. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) results suggested that PTK2 and co-expressed genes participated in the cell cycle. Immune infiltration analysis clarified that high PTK2 expression was positively correlated with infiltrating levels of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. The DNA methylation of PTK2 in breast cancer tissues was higher than that in normal tissues, and high PTK2 methylation was correlated with poor prognosis in breast cancer patients. Furthermore, 16 possible ceRNA networks related to PTK2 were constructed for breast cancer. Additionally, PTK2 knockdown could suppress the proliferation and migration ability of MCF-7 cells. These results suggest that PTK2 can be used as a prognostic biomarker for breast cancer.Copyright © 2022 Chen, Wang, Fang, Zhang and Deng.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区生物学

小类 | 3 区生化与分子生物学

最新[2023]版：

大类 | 3 区生物学

小类 | 3 区生化与分子生物学

第一作者：

第一作者机构： [1]North Sichuan Medical College, Institute of Basic Medicine and Forensic Medicine, Sichuan, China. [2]Sichuan Key Laboratory of Medical Imaging and school of Medicine Imaging, North Sichuan Medical College, Sichuan, China. [3]Department of Academician (expert) Workstation, Biological Targeting Laboratory of Breast Cancer, Breast and Thyroid Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan, China.

共同第一作者：

通讯作者：

通讯机构： [1]North Sichuan Medical College, Institute of Basic Medicine and Forensic Medicine, Sichuan, China. [2]Sichuan Key Laboratory of Medical Imaging and school of Medicine Imaging, North Sichuan Medical College, Sichuan, China. [3]Department of Academician (expert) Workstation, Biological Targeting Laboratory of Breast Cancer, Breast and Thyroid Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma [2]MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer. [3]乳腺癌相关成纤维细胞：乳腺癌治疗的新靶点 [4]Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis [5]Upregulation of circ_0008812 and circ_0001583 predicts poor prognosis and promotes breast cancer proliferation [6]High serum uric acid concentration predicts poor survival in patients with breast cancer [7]Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer [8]血浆长链非编码RNA HOTAIR是乳腺癌诊断的潜在生物标志物 [9]FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction. [10]Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer